IFNG and chronic myelogenous leukemia, BCR-ABL1 positive: While IFNγ seems capable of acting as an anti-tumorigenic factor in CML patients (indirectly, through the activation of a multitude of cellular components of the immune system),24 several publications show that it can also exert direct anti-apoptotic, pro-proliferative and pro-clonogenic effects on CML cells, both in the absence and presence of TKIs.12,13,25